ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Dr. Reddy's Laboratories Ltd.

  • 2,278.00 INR
  • -69.95
  • -2.98%
  • India
    Aug 16, 2018
  • Ticker
    BOM(500124)
  • Prev. close
    2,347.95
  • Market cap (INR)
    389,613.15M
  • Market cap (USD)
    5,542.44M
  • Shares
    165.93M

Business Summary

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Financial Highlights

Mar 2018 INRUSD
Revenue142,028M2,203.14M
Gross Profit71,189M1,104.28M
Operating income11,182M173.45M
Income before tax13,997M217.12M
Net income9,806M152.11M
EBITDA22,892M355.10M
Diluted EPS59.010.91
Dividends Per Share200.31
Total Assets225,604M3,459.03M
Total liabilities99,144M1,520.10M
Total equity126,460M1,938.92M
Operating cash flow17,110M265.41M
Currency in INRCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 132,170M 148,189M 154,708M 140,809M 142,028M
Gross Profit 72,466M 81,457M 87,272M 73,531M 71,189M
Operating income 24,119M 25,878M 28,806M 12,878M 11,182M
Income before tax 26,432M 27,968M 26,911M 14,304M 13,997M
Net income 21,515M 22,179M 20,013M 12,039M 9,806M
EBITDA 31,225M 33,978M 39,056M 24,155M 22,892M
Diluted EPS 126.04 129.75 116.99 72.09 59.01
Dividends Per Share 18 20 20 20 20
Total Assets 170,223M 194,762M 207,650M 219,821M 225,604M
Total liabilities 79,422M 83,460M 79,314M 95,777M 99,144M
Total equity 90,801M 111,302M 128,336M 124,044M 126,460M
Operating cash flow 19,280M 24,760M 41,613M 21,216M 17,110M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 2,187.00M 2,423.62M 2,363.00M 2,099.83M 2,203.14M
Gross Profit 1,199.08M 1,332.22M 1,332.99M 1,096.54M 1,104.28M
Operating income 399.09M 423.23M 439.98M 192.04M 173.45M
Income before tax 437.36M 457.41M 411.03M 213.31M 217.12M
Net income 356.00M 362.73M 305.67M 179.53M 152.11M
EBITDA 516.67M 555.70M 596.54M 360.21M 355.10M
Diluted EPS 2.08 2.12 1.78 1.07 0.91
Dividends Per Share 0.29 0.32 0.30 0.29 0.31
Total Assets 2,850.23M 3,112.14M 3,135.64M 3,385.24M 3,459.03M
Total liabilities 1,329.85M 1,333.62M 1,197.68M 1,474.96M 1,520.10M
Total equity 1,520.38M 1,778.51M 1,937.95M 1,910.27M 1,938.92M
Operating cash flow 319.02M 404.94M 635.59M 316.38M 265.41M

Valuation Measures

Mar 2018
PER35.21
ROA4.40%
ROE7.82%
Operating margin7.87%
Profit margin6.90%

Key executives

  • Co-Chairman, Chief Executive Officer & MD: Gunupati Venkateswara Prasad
  • President, CFO & Global Head-IT: Saumen Chakraborty
  • Chief Operating Officer & Global Head-Generics: Erez Israeli
  • Secretary & Compliance Officer: Sandeep Poddar
  • Executive Vice President & Head-Biologics: Cartikeya Reddy

Shareholders

  • Dr. Reddy's Holdings Ltd. (24.7%)
  • First State Investment Management (UK) Ltd. (6.1%)
  • Life Insurance Corp. of India (4.4%)
  • OppenheimerFunds, Inc. (3.8%)
  • Reliance Nippon Life Asset Management Ltd. (Invt Mgmt) (2.5%)
  • Aditya Birla Sun Life AMC Ltd. (2.2%)
  • Franklin Advisers, Inc. (1.9%)
  • Franklin Templeton Asset Management (India) Pvt Ltd. (1.9%)
  • BlackRock Fund Advisors (1.8%)
  • ICICI Prudential Asset Management Co. Ltd. (1.2%)

Contact Details

  • Website:http://www.drreddys.com
  • Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
  • Phone: +91.40.49002900

Related Companies

  • Dr. Reddy's New Zealand Ltd.
  • Imperial Credit Pvt Ltd.
  • Ducere Pharma LLC/Otc Bus/
  • UCB SA /Established Product Bus/
  • Dr. Reddy's Laboratories SA
  • Dr. Reddy's Laboratories Ltd. (Russia)
  • Zenovus Biotech Pvt Ltd.
  • Reddy Holding GmbH
  • Dr. Reddy's Pharma SEZ Ltd.
  • Dr. Reddy's Bio-Sciences Ltd.
  • Promius Pharma LLC
  • Industrias Quimicas Falcon de Mexico SA de CV
  • DR Reddy's Laboratories (UK) Ltd.
  • Kunshan Rotam Reddy Pharmaceutical Co. Ltd.
  • Perlecan Pharma Pvt Ltd.
  • Macred India Pvt Ltd.
  • BASF SE /Pharmaceutical Contract Manufacturing Unit/
  • Reddy Pharma Italia SpA
  • Dowpharma /Small Molecules Business/
  • Dr. Reddy's Laboratories, Inc.
  • Laboratorios Litaphar SA
  • F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
  • Trigenesis Therapeutics, Inc.
  • betapharm Arzneimittel GmbH
  • OctoPlus N.V.
  • Dr. Reddy's Laboratories (EU) Ltd

Competitors

  • Novartis AG
  • Perrigo Co. Plc
  • Mylan N.V.
  • Pfizer Inc.
  • KRKA dd
  • Sanofi
  • Pfizer India Ltd.
  • Cipla Limited
  • Teva Pharmaceutical Industries Limited
  • Chemical Works of Gedeon Richter Plc
  • GlaxoSmithKline Pharmaceuticals Limited
  • Lupin Limited
  • Sanofi India Limited
  • Bayer AG
  • Takeda Pharmaceutical Co. Ltd.
  • Endo International Plc
  • Alkem Laboratories Ltd.
  • STADA Arzneimittel AG
  • Cadila Healthcare Limited
  • Sun Pharmaceutical Industries Limited
  • Abbott India Limited
  • Piramal Enterprises Ltd.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithkline Consumer Healthcare Ltd
  • Divi's Laboratories Limited
  • Aurobindo Pharma Ltd
  • Catalent Inc
  • Dishman Carbogen Amcis Ltd.
  • Thermo Fisher Scientific Inc.
  • Cambrex Corporation
Last Updated on 16 Aug, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media